Patent ID: 6303321
Filing Date: 2001-10-16
Classification: A61K,A61P,C07K,G01N,Y02A

Abstract:
A diagnostic and prognostic method for monitoring the severity and predicting the likely clinical course of sepsis for a mammalian subject exhibiting shock-like symptoms or at risk to exhibit symptoms associated with conditions characterized by activation of the inflammatory cascade, comprising measuring the concentration of HMG1 in a test sample from the mammalian subject, and comparing that concentration to a standard for HMG1 representative of a concentration range of HMG1 in mammals of the same species as the mammalian subject not having sepsis, whereby a level of HMG1 in the test sample higher than the standard indicates a diagnosis of sepsis and whereby the magnitude of the difference between the level of HMG1 in the test sample and the standard positively correlates with the severity of sepsis and with a poor prognosis of the course of sepsis.